Coherus Oncology (CHRS) Cost of Revenue (2019 - 2026)

Coherus Oncology (CHRS) has 8 years of Cost of Revenue data on file, last reported at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 43.76% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $15.0 million (up 50.64% YoY), and the FY2025 full-year result was $13.8 million, up 58.29% from the prior year.
• Cost of Revenue declined to $3.8 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $84.6 million in Q4 2023 to a low of $1.4 million in Q1 2024.
• A 5-year average of $15.0 million and a median of $4.0 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 495.46% in 2023 and tumbled 96.75% in 2024, its largest moves.
• Tracing CHRS's Cost of Revenue over 5 years: stood at $14.2 million in 2022, then surged by 495.46% to $84.6 million in 2023, then plunged by 96.75% to $2.8 million in 2024, then soared by 47.09% to $4.0 million in 2025, then dropped by 5.71% to $3.8 million in 2026.
• Business Quant data shows CHRS's Cost of Revenue at $3.8 million in Q1 2026, $4.0 million in Q4 2025, and $3.7 million in Q3 2025.